期刊文献+

基于二层特征筛选的HIV-1蛋白酶特异位点预测 被引量:1

HIV-1 protease cleavage site prediction based on two stage feature selection method
在线阅读 下载PDF
导出
摘要 在抗艾滋病治疗中,HIV-1蛋白酶抑制剂发挥着重要作用。对于HIV-1蛋白酶裂解作用位点的研究有助于找到新的治疗靶点。为了对HIV-1蛋白酶特异位点进行预测,本研究用氨基酸索引数据库(Amino Acid Index,AAIndex)中的531个氨基酸物理化学性质参数直接表征肽样本的结构,通过二层特征筛选,最终将4248个表征参数降为57个表征参数。分别采取四种核函数进行HIV-1蛋白酶特异位点的支持向量机(SVM)建模,并通过10折交叉验证及外部测试集方法来验证建模的准确性。结果表明选取NormalizePolyKernel核函数进行SVM建模效果优于其他核函数(PolyKernel、PUK、RBFKernel),所建立的模型对于训练集的10组交叉验证预测准确率达到93.947%,对于外部测试集的预测正确率达到93.684%。 The HIV - 1 protease inhibitor plays an important role in the therapy of AIDS. The research on HIV - 1 protease' s cleavage site will be useful to found new therapeutic targets. To predict the HIV - 1 protease specific site, we apply Amino Acid Index(AAIndex) ' s 531 amino acid' s parameter of chemical and physical to present the structure of peptide sample. And based on two stage feature selection method , 57 features are selected from origi- nal 4248 features. By using four kernel function of support vector machine ( SVM), HIV - 1 protease specific site' s model is built. Our research showed the modeling by the kernel function of NormalizePolyKernel had the higher prediction rate than other three kernel function. As a result, the accuracy rate of prediction achieves 93. 947 % and 93. 684% for corss validation test and an independent set test, respectively.
出处 《生物信息学》 2012年第4期274-279,共6页 Chinese Journal of Bioinformatics
基金 上海市优秀青年教师基金(SHU10022) 国家自然科学基金(20973108)
关键词 变量筛选 支持向量机 10折交叉验证 预测模型 HIV-1蛋白酶 Feature selection SVM ( support vector machine) 10 - crossvalidation Prediction model HIV - 1protease
  • 相关文献

参考文献25

  • 1Appett k. Crystal structures of HIV - 1 protease - inhibitors com- plexes[ J]. Persp Drug Discov Des. 1993,1 : 1993.
  • 2陈凯先,蒋华良,稽汝运.计算机药物辅助设计-原理、方法及应用[M].北京:化学工业出版社,2000.
  • 3Kramer RA, Sehaber MD, Skalla AM. HTLV - iIi gag protein is processed in yeast cells by the virus pol - protease [ J ]. Science. 1986,231 : 1580 - 1584.
  • 4Beck ZQ, Hervio, L. , Dawson, P. E. , Elder, J. E. , Madison, E. L. Identification of efficiently cleaved substrates for HIV - 1 protease using a phage display library and use in inhibitor development [ J ]. Virology,2000,75:9502 - 9508.
  • 5Cofn,J. What to call the AIDS virus? [ J ]. Nature, 1986,321: 10.
  • 6Schechter I, Berger A. On the size of the active site in proteases [ J]. Biochem Biophys Res Commun, 1967,27 : 157 - 162.
  • 7Kim HL, Oh B, Kimm K, Koh I. Prediction of phosphorylation site- susing SVMs[J]. Bioinformatics,2004,20:3179- 3184.
  • 8Thompson, T. B. ; Chou, K. C. ; Zheng, C. , Neural network prediction of the HIV - 1 protease cleavage sites [ J ]. Journal of Theoretical Biology, 1995, 177 (4) : 369 - 379.
  • 9Cai, Y. D. , Yu, H. , Chou, K.C.. Using neural network for prediction of HIV protease cleavage sites in proteins [ J ]. J. Pro- tein Chem,1998 ,17 :607- 615.
  • 10Thompson, T. B. ; Chou, K. C. ; Zheng, C. T. , Neural net- work prediction of the HIV - 1 protease cleavage sites [ J ]. J. Theoret. Bio1,1995, 177:369- 379.

同被引文献26

  • 1MOORE C, CIARALD E. Quality of care and service expan- sion for HIV care and treatment[J] .Current HIV/AIDS Re- ports, 2015, 12(2): 223-230.
  • 2MCGETTIGAN J, NAPER K, ORENSTEIN J, et al. Func- tional human immunodeficiency virus type 1 (HIV-1) Gag- Pol or HIV-1 Gag-Pol and env expressed from a single rhab- dovirus-based vaccine vector genome [J]. Journal of Virolo- gy, 2003, 77(20): 10889-10899.
  • 3ADAMSON C. Protease-mediated maturation of HIV : inhibi- tors of protease and the maturation process[ J] .Molecular Bi- ology International, 2012,604261 : 1-13.
  • 4HAYASHI H, TAKAMUNE N, NIRASAWA T, et al. Dimer- ization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir [ J ]. Proceedings of the National Academy of Sci- ences, 2014,111 (33) : 12234-12239.
  • 5DEBOUCK C. The HIV-1 protease as a therapeutic target for AIDS[ J].AIDS Research and Human Retroviruses, 1992, 8 (2) : 153-164.
  • 6POTEMPA M, LEE S, WOLFENDEN R, et al. The triple threat of HIV-1 protease inhibitors[ J] .Current Topics in Mi- crobiology and Immunology, 2015, 389: 203-241.
  • 7HOU L, WANG H, DUAN S, et al. The prevalence and de- terminants of drug-resistance-associated mutations in the HIV-linfected MSM population of Henan Province in China [ J ].Archives of Virology, 2015,160 (8) : 2051- 2061.
  • 8VISPO E.Waming on hepatotoxicity of darunavir[ J] .AIDS Reviews, 2008, 10(1) : 62-63.
  • 9LIN K, CHENG C, YANG C, et al. Skin rash related to once-daily boosted darunavir-containing antiretroviral thera- py in HIV-infected Taiwan Residents: incidence and associated factor[ J] .Journal of Infection and Chemotherapy, 2014,20 (8) :465-470.
  • 10LAVECCHIA A.Machine-leaming approaches in drug dis- covery : methods and applications [ J ]. Drug Discovery To- day,2015,20(3) :318-331.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部